Sermorelin vs Ipamorelin vs CJC-1295: Complete Comparison Guide (2026)

Growth hormone peptides have become some of the most researched compounds in the longevity and performance space — and Sermorelin, Ipamorelin, and CJC-1295 sit at the top of that list. But the way these three peptides are discussed online tends to create more confusion than clarity. They all stimulate GH release, yet they work through different mechanisms, have dramatically different pharmacokinetic profiles, and are used in different clinical contexts.

This guide breaks down each peptide individually, then compares them head-to-head across every dimension that matters: mechanism, half-life, dosing protocols, side effects, cost, and ideal use cases. By the end, you’ll have a clear picture of how these compounds differ and which profile fits which goal.

Research Notice: This content is for educational and research purposes only. Sermorelin, Ipamorelin, and CJC-1295 are prescription compounds or research peptides. Any use in humans requires physician oversight. Nothing here constitutes medical advice.

---

At a Glance: Quick Comparison Table

Feature	Sermorelin	CJC-1295 (no DAC)	Ipamorelin
Peptide class	GHRH analog	GHRH analog	Ghrelin mimetic (GHRP)
Amino acids	29	30 (modified)	5
Half-life	10–20 minutes	~30 minutes	~2 hours
GH increase	2–3× baseline	3–5× baseline	2–4× baseline
IGF-1 elevation	Moderate	Moderate–High	Moderate
Cortisol effect	None	None	None
Prolactin effect	None	None	None
Appetite stimulation	None	None	Minimal
FDA history	Was FDA-approved (Geref, 1990s)	Research compound	Research compound
Typical dosing	200–500 mcg/day	100–300 mcg/dose	100–300 mcg/dose
Injection frequency	1–2× daily	1–3× daily	1–3× daily (usually stacked)
Typical monthly cost	$100–$200	$150–$300 (usually as stack)	$150–$300 (usually as stack)
Best use case	Entry-level, gentle GH support	Stronger GH release, stacking	Combined with CJC-1295 for synergy

---

Understanding the Landscape First

Before diving into individual profiles, one framing point that context often omits: Ipamorelin is almost never used alone. It is overwhelmingly prescribed as part of a CJC-1295 + Ipamorelin combination stack. The two peptides work through completely different receptor pathways and produce a synergistic GH pulse when used together — far greater than either alone.

So the real decision for most people researching these peptides is:

• Sermorelin monotherapy — the simpler, gentler option with a longer safety record
• CJC-1295 + Ipamorelin stack — the more potent modern approach used in most clinical protocols

With that context established, here’s what each peptide actually is.

---

Sermorelin: The Original GH Secretagogue

Mechanism of Action

Sermorelin is a synthetic analog of the first 29 amino acids of human growth hormone-releasing hormone (GHRH). The full GHRH peptide contains 44 amino acids, but the biologically active portion that binds the pituitary GHRH receptor is contained within those first 29 residues — making Sermorelin functionally equivalent to endogenous GHRH.

When injected, Sermorelin binds the GHRH receptor on somatotroph cells in the anterior pituitary, triggering the natural GH release cascade. Because it acts through the brain’s normal feedback loop (the hypothalamic-pituitary axis), it preserves physiological GH pulsatility — pulses occur within the body’s natural regulatory framework, and somatostatin (the GH-braking hormone) still exerts its normal dampening effect. This is why Sermorelin is often described as the most “physiological” option.

Half-Life and Pharmacokinetics

Sermorelin has a very short plasma half-life of approximately 10–20 minutes. After subcutaneous injection, it is rapidly cleaved by endopeptidases in the bloodstream. This means the GH pulse it triggers is brief and relatively modest compared to longer-acting analogs.

The short half-life has practical implications: timing of injection matters considerably. Most protocols call for administration before bed to coincide with the largest endogenous GH pulse that normally occurs during slow-wave sleep.

Dosing Protocol

Typical clinical range: 200–500 mcg per injection
Frequency: 1–2 injections daily, typically before bed
Administration: Subcutaneous injection
Cycle length: 3–6 months minimum for meaningful IGF-1 changes; often used as ongoing therapy

Some protocols add a morning injection in patients seeking more pronounced daytime effects, but single nightly dosing is the most common clinical approach.

Side Effects

Sermorelin’s side effect profile is notably mild:

• Injection site reactions — mild redness or transient discomfort (most common)
• Facial flushing — brief warmth after injection, resolves within minutes
• Headache — mild, infrequent
• Water retention — mild, especially in the first few weeks; diminishes with continued use
• Dizziness — rare

Notably absent are the cortisol, prolactin, and appetite effects associated with older GHRPs (like GHRP-2 and GHRP-6). Sermorelin does not produce meaningful elevations in these hormones.

Safety track record: Sermorelin carries the longest clinical record of any GH secretagogue. The original branded formulation (Geref) was FDA-approved in the 1990s. While that approval has since lapsed and the brand has been discontinued, the research foundation from that era gives Sermorelin a documented safety profile that CJC-1295 and Ipamorelin do not yet match in terms of regulatory history.

Cost

Estimated monthly cost: $100–$200 through compounding pharmacies with a prescription
Sermorelin is generally the most affordable option among the three peptides, partly because it’s a simpler molecule and has been manufactured at scale for longer.

Best Use Cases

• Patients new to GH peptide therapy wanting the most conservative entry point
• Older adults with mild-to-moderate age-related GH decline
• Those who prefer a compound with historical FDA approval history
• Protocols emphasizing physiological mimicry over raw potency
• Patients for whom cost is a significant consideration

---

CJC-1295: The Upgraded GHRH Analog

Mechanism of Action

CJC-1295 is also a GHRH analog, but it’s meaningfully different from Sermorelin in structure. It’s a 30-amino-acid peptide engineered with several key amino acid substitutions that accomplish two things: (1) significantly increase binding affinity for the GHRH receptor, and (2) dramatically increase resistance to enzymatic degradation in plasma.

The result is a GHRH analog that produces a 3–5× greater GH pulse than Sermorelin at comparable doses and stays active long enough to produce more sustained receptor stimulation.

An important clarification on CJC-1295 versions: CJC-1295 comes in two distinct forms that are frequently confused:

• CJC-1295 with DAC (Drug Affinity Complex): A long-acting version that binds to albumin in the blood for a plasma half-life of approximately 8 days. It produces a sustained, non-pulsatile GH elevation often called a “GH bleed.” Administered once weekly.
• CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF): The shorter-acting version with a half-life of approximately 30 minutes. Produces a pulsatile GH release pattern. This is the version used in virtually all clinical stack protocols with Ipamorelin.

When people discuss “CJC-1295 + Ipamorelin,” they almost universally mean the without-DAC version. The DAC version is controversial because sustained, non-pulsatile GH elevation may not replicate healthy physiology and raises questions about long-term IGF-1 elevation patterns.

Half-Life and Pharmacokinetics

• Without DAC: ~30 minutes — produces a clean GH pulse, timing-sensitive
• With DAC: ~8 days — produces sustained baseline GH elevation, once-weekly dosing

Dosing Protocol

Without DAC (clinical standard):

• Dose: 100–300 mcg per injection
• Frequency: 1–3× daily, often stacked with Ipamorelin at the same time
• Timing: Fasting state (at least 2–3 hours post-meal); before bed and/or upon waking

With DAC (less common):

• Dose: 1,000–2,000 mcg
• Frequency: Once weekly
• Used in some anti-aging protocols; generally not the first-line choice

Side Effects

CJC-1295 shares Sermorelin’s mild side effect profile, with the same low incidence of:

• Injection site redness or discomfort
• Facial flushing post-injection
• Mild water retention early in therapy
• Occasional headache or fatigue

The DAC form carries additional theoretical concern around prolonged IGF-1 elevation — sustained elevation of IGF-1 is a consideration that physicians weigh when choosing between CJC formulations.

No significant cortisol, prolactin, or appetite effects have been documented for either form of CJC-1295 — a key advantage over older first-generation GHRPs.

Cost

Estimated monthly cost (without DAC, as part of CJC + Ipamorelin stack): $150–$300
CJC-1295 is typically sold in combination vials with Ipamorelin, making it difficult to separate costs. Combined stack pricing from compounding pharmacies generally runs $150–$300/month depending on dose and provider.

Best Use Cases

• Patients seeking stronger GH release than Sermorelin provides
• Those who have plateaued on Sermorelin monotherapy
• Stack protocols combined with Ipamorelin (the dominant clinical approach)
• Patients prioritizing potency within the GHRH analog class
• Muscle preservation and body composition goals requiring meaningful IGF-1 elevation

---

Ipamorelin: The Selective GHRP

Mechanism of Action

Ipamorelin is fundamentally different from both Sermorelin and CJC-1295 at the receptor level. Rather than acting on the GHRH receptor, it is a ghrelin mimetic — it binds the growth hormone secretagogue receptor (GHS-R1a), also called the ghrelin receptor. This is a completely separate receptor pathway from the one GHRH analogs target.

This distinction matters because the pituitary has two distinct trigger points for GH release: the GHRH receptor and the ghrelin receptor. Stimulating both simultaneously produces a GH pulse significantly larger than stimulating either alone — a synergistic effect. This is the scientific foundation for combining CJC-1295 and Ipamorelin.

Ipamorelin is classified as a third-generation GHRP, representing a significant advancement over earlier ghrelin mimetics:

• First-generation: GHRP-6 (effective but causes significant appetite stimulation and cortisol elevation)
• Second-generation: GHRP-2 (more potent, still causes cortisol and prolactin elevation)
• Third-generation: Ipamorelin (selective GH release, minimal off-target hormonal effects)

The selectivity of Ipamorelin for the GHS-R1a receptor — without meaningful activation of cortisol or prolactin pathways — makes it the cleanest GHRP currently available for clinical use.

Half-Life and Pharmacokinetics

Ipamorelin has a plasma half-life of approximately 2 hours — significantly longer than both Sermorelin and CJC-1295 without DAC. This extended half-life contributes to a more sustained GH pulse when used in combination, and gives more flexibility in injection timing compared to the GHRH analogs.

Dosing Protocol

Typical clinical range: 100–300 mcg per injection
Frequency: 1–3× daily; virtually always administered simultaneously with CJC-1295 (no DAC)
Timing: Same timing principles as CJC-1295 — fasting state preferred; before bed and/or upon waking
Common stack dose: 100 mcg Ipamorelin + 100 mcg CJC-1295, 1–2× daily

When dosed as a combined injection (which most compounding pharmacies provide in a single vial), the GH pulse from the CJC-1295 + Ipamorelin combination reliably exceeds what either peptide produces individually.

Side Effects

Ipamorelin is among the best-tolerated peptides in the GH secretagogue class:

• Injection site reactions — same mild, transient responses as the others
• Headache — mild, resolves quickly; more common when starting therapy
• Facial flushing — brief, post-injection
• Water retention — mild early in therapy

What Ipamorelin does NOT cause (distinguishing it from earlier GHRPs):

• Significant cortisol elevation
• Prolactin elevation
• Meaningful appetite stimulation (a key improvement over GHRP-6)

Cost

Estimated monthly cost (as part of CJC + Ipamorelin stack): $150–$300 combined
Ipamorelin is rarely priced separately because it’s nearly always combined with CJC-1295. Stack pricing is comparable to Sermorelin, though protocols often require higher doses for equivalent effect timelines.

Best Use Cases

• The synergistic “half” of the CJC-1295 + Ipamorelin stack
• Patients who previously experienced cortisol or appetite side effects on GHRP-6 or GHRP-2
• Those prioritizing selective GH release without hormonal off-target effects
• Recovery optimization, fat loss, and sleep quality improvement
• Anti-aging protocols where cortisol management is a priority

---

Head-to-Head: Key Decision Factors

Potency

Winner: CJC-1295 + Ipamorelin stack
The synergistic combination produces the largest, most consistent GH pulses of any option reviewed here. Sermorelin’s 2–3× GH increase cannot match the 3–5× seen with CJC-1295 alone, and the addition of Ipamorelin’s ghrelin pathway stimulation adds further amplitude.

Safety Track Record

Winner: Sermorelin
Sermorelin’s historical FDA approval (even though lapsed) and decades of documented clinical use give it an unmatched safety record in this group. CJC-1295 and Ipamorelin have strong safety profiles in available studies, but their long-term records don’t yet match Sermorelin’s.

Selectivity (Off-Target Effects)

Winner: Ipamorelin (among GHRPs)
Compared to first- and second-generation GHRPs, Ipamorelin’s selectivity for GH release without cortisol or prolactin co-stimulation is a genuine advancement. Both GHRH analogs (Sermorelin, CJC-1295) are also clean in this regard.

Convenience

Winner: Sermorelin (for simplicity); CJC-1295 + Ipamorelin (for combined protocols)
Sermorelin’s once-daily protocol is operationally simpler. CJC-1295 + Ipamorelin stacks typically require 1–3 daily injections, though combination vials eliminate the need for separate injections.

Half-Life / Flexibility

Winner: Ipamorelin
Ipamorelin’s ~2-hour half-life provides more dosing flexibility than either GHRH analog. This doesn’t change the recommendation for most users but matters for travel or schedule-sensitive protocols.

Cost Efficiency

Winner: Sermorelin
At $100–$200/month vs. $150–$300+ for the CJC-1295 + Ipamorelin stack, Sermorelin is the most cost-accessible option. However, if higher potency means shorter duration to goal, the stack may be more cost-effective long-term.

Best for Beginners

Winner: Sermorelin
The conservative side effect profile, simpler dosing, and longest safety record make Sermorelin the logical starting point for most first-time GH peptide users.

---

Clinical Use Patterns: What Prescribers Actually Do

Based on published clinical data and reported prescribing patterns, these are the most common real-world protocols:

Protocol 1 — Conservative / Entry Level:
Sermorelin 200–300 mcg before bed, 5 days/week. Used for older adults, mild GH deficiency, or patients new to peptide therapy.

Protocol 2 — Standard Stack (most common):
CJC-1295 (no DAC) 200 mcg + Ipamorelin 200 mcg, combined injection, 1–2× daily (before bed; optionally also upon waking). Used for most muscle-building, fat loss, anti-aging, and recovery applications.

Protocol 3 — Escalation Protocol:
Start with Sermorelin monotherapy for 1–3 months to establish baseline response and tolerance. Transition to CJC-1295 + Ipamorelin stack for stronger ongoing effects.

---

Summary: Which Peptide Is Right for Which Goal?

Goal	Recommended Approach
Trying GH peptides for the first time	Sermorelin monotherapy
Maximum GH pulse amplitude	CJC-1295 + Ipamorelin stack
Muscle preservation / body composition	CJC-1295 + Ipamorelin stack
Fat loss	CJC-1295 + Ipamorelin stack
Recovery optimization	CJC-1295 + Ipamorelin stack
Sleep quality improvement	Sermorelin or Ipamorelin-containing stack
Gentlest hormonal profile	Sermorelin
Older adult with pituitary decline	CJC-1295 + Ipamorelin stack (more potent stimulation needed)
Budget-conscious approach	Sermorelin
Already on Sermorelin, want more effect	Upgrade to CJC-1295 + Ipamorelin

---

Important Considerations Before Use

Prescription and sourcing: Sermorelin requires a physician prescription in the United States and most countries. CJC-1295 and Ipamorelin are not FDA-approved and are available through compounding pharmacies with a physician’s order or as research-grade compounds for laboratory use. Obtaining these compounds without medical supervision carries legal and safety risks.

Baseline testing: Responsible clinical protocols include IGF-1 blood testing before and during therapy to track response and avoid over-supplementation. IGF-1 normalization (not maximization) is the clinical goal.

Peptide quality: Research-grade peptide purity and proper storage (typically lyophilized and refrigerated) are critical. Peptide degradation, contamination, and mislabeling are real concerns when sourcing outside regulated channels.

Individual variability: Response to GH secretagogues varies substantially between individuals based on age, baseline GH status, pituitary responsiveness, and lifestyle factors. What produces a strong response in one person may produce minimal effect in another.

---

The Bottom Line

Sermorelin, CJC-1295, and Ipamorelin all represent legitimate, well-studied approaches to growth hormone secretagogue therapy — but they occupy different positions on the potency-simplicity spectrum.

Sermorelin is the conservative entry point: gentler, better-documented historically, more affordable, and appropriate for those seeking the most physiological option.

CJC-1295 + Ipamorelin is the dominant modern protocol: more potent, synergistic by design, and the approach most clinicians reach for when meaningful GH elevation is the goal.

Ipamorelin alone is not how this molecule is typically used. Its value is as the ghrelin-pathway complement to the GHRH-pathway stimulation of CJC-1295.

For most people whose research brings them to this comparison, the practical choice is: start with Sermorelin if you want caution and simplicity, or go straight to the CJC-1295 + Ipamorelin stack if you want the strongest evidence-based approach currently in clinical use.

---

This article is for research and informational purposes only. HelixVault does not sell peptides or other compounds. All content reflects publicly available scientific literature and reported clinical practice. Consult a licensed healthcare provider before initiating any peptide therapy.